Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior.
about
The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testingNodal and leukemic small B-cell neoplasmsThe biology behind PI3K inhibition in chronic lymphocytic leukaemiaRichter transformation of CLL.TP53 Staining in Tissue Samples of Chronic Lymphocytic Lymphoma Cases: An Immunohistochemical Survey of 51 CasesHigh rate of neoplastic cells with genetic abnormalities in proliferation centers of chronic lymphocytic leukemia.Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia.Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapyBruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes.ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulationReassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis.Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphomaMembrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells.T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Chronic lymphocytic leukemia/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression.The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial.MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.Hsa-miR-15a and Hsa-miR-16-1 expression is not related to proliferation centers abundance and other prognostic factors in chronic lymphocytic leukemia.Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.Lymphoma classification update: B-cell non-Hodgkin lymphomas.Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review.Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.2016 WHO Classification update-What's new in lymphoid neoplasms.Cytologic perspectives on neoteric B-cell lymphoproliferative disorders.Richter Syndrome in Chronic Lymphocytic Leukemia.PET-positive lymphadenopathy in CLL-Not always Richter transformation.Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia.Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature.A 61-year-old male with generalised lymphadenopathy presenting with shortness of breath and infiltrates on chest radiography.Treatment of Richter's Syndrome.Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays.Apoptotic and proliferative characteristics of proliferation centers in lymph node sections of patients with chronic lymphocytic leukemia.Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.B-cell lymphomas with discordance between pathological features and clinical behavior.An unusual case of chronic lymphocytic leukemia/small lymphocytic lymphoma with nodular morphology.
P2860
Q26784600-E9EA796C-F6EB-48D2-8328-0973C6706960Q26829315-6224AFFB-7823-4634-88EB-83FE3A7511EEQ28083266-983480C1-01B1-401F-902F-4286A63FD126Q30249283-39F15211-48B3-439E-A238-CC353D558FDEQ33747801-0A695581-6934-4A93-ABB7-0FB8B48DD2C4Q33850156-8986AC3C-3853-4C61-810A-0EC0460C104AQ34009015-C98C0B78-6BA1-4CF1-B535-53A9E4E1995DQ34020276-83714CA7-A08B-4534-B6B4-CE42A070A858Q34026194-7277346C-B1A2-4A60-8175-E5A4C234BCE3Q35020381-3FEE4F7B-9269-4604-A7FF-C73EBB35DF0EQ35061209-CEF7D32B-0656-468C-9A1B-9B02A35A067CQ35143475-8F9B2B0D-97B8-4D31-A9B7-3C8D35F7BD4AQ35569501-FBE3BEDB-E440-47C5-B2BF-FA571363C54EQ35717890-2DFFB021-DB59-4F90-AD3A-06FE81BDCD08Q36245171-431442C8-27B1-41E6-94AA-D74746A740BBQ36920426-D77F786F-FFDB-47A1-ADDF-4635EA4189BBQ36979738-98B22D00-E9D3-466B-B741-C2F114409BE8Q37199470-161C34D1-79F7-4BE6-8FFB-7DF4916A9CCFQ37212700-E798AB10-BFE3-4E1F-89FF-7962F3FA5046Q37417412-E118AB36-A1A2-472E-8D36-52621D7474F0Q38663689-C841CE16-FF1C-45A9-B42B-46531E4BC093Q38843988-16352B99-E466-494B-9FE0-B0BF874C1544Q38877593-4A832F1B-4F68-4ECA-B81E-76223DF18172Q38896306-216C1862-AA2E-4947-8310-4C2EC69B3EE8Q39034465-78EFD738-96A0-4080-B7B2-1A8B7A8C3A8BQ39266295-18E98220-6C74-47E0-9C4A-AD2D320B4341Q39359287-FA69DCF8-B0CE-455F-9382-73AC1021E7EFQ40037434-74B478F7-D897-41CA-8273-6B19C0E61868Q40525862-1ECF4FB9-CE58-46E8-9578-812E50AC48B6Q41481956-7D725F56-46DF-4AA3-A522-C6E924170E7BQ42434778-61698E0A-492B-4FD3-A2CD-D2FF2E69E10AQ44741136-938396A4-6F3E-4E42-B7D2-B4955C5166F7Q47156785-2EF9BA65-074E-4A69-AC77-949E58024F9FQ49843910-23E892A8-4F4E-4E20-8FE4-45045770930BQ50074012-D7D6CD9D-987A-455B-99D6-D080B7C1C150Q50790201-505898BD-7D13-4F98-99C4-9B5C42E224F0Q50970605-EE68741D-6077-4418-AB67-BC8274598BC4Q51749083-42B860CC-CF39-473B-AD85-444E29CADECFQ52863282-CB6BCE01-C92F-4EE2-AAD9-67027AC9C053Q52949170-28EEEC05-89A8-43B3-B5E4-FA54497D6EB7
P2860
Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Expanded and highly active pro ...... aggressive clinical behavior.
@ast
Expanded and highly active pro ...... aggressive clinical behavior.
@en
Expanded and highly active pro ...... f chronic lymphocytic leukemia
@nl
type
label
Expanded and highly active pro ...... aggressive clinical behavior.
@ast
Expanded and highly active pro ...... aggressive clinical behavior.
@en
Expanded and highly active pro ...... f chronic lymphocytic leukemia
@nl
prefLabel
Expanded and highly active pro ...... aggressive clinical behavior.
@ast
Expanded and highly active pro ...... aggressive clinical behavior.
@en
Expanded and highly active pro ...... f chronic lymphocytic leukemia
@nl
P2093
P2860
P50
P1433
P1476
Expanded and highly active pro ...... aggressive clinical behavior.
@en
P2093
Ana Muntañola
Antoni Martinez
Armando López-Guillermo
Ciril Rozman
Emili Montserrat
Jordi Esteve
Neus Villamor
Pau Abrisqueta
P2860
P304
P356
10.3324/HAEMATOL.2010.022277
P577
2010-04-26T00:00:00Z